+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
COX-2 Selective NSAIDs Market by Route, Dosage Form, Product, Indication, Distribution Channel, End User - Global Forecast to 2030- Product Image
COX-2 Selective NSAIDs Market by Route, Dosage Form, Product, Indication, Distribution Channel, End User - Global Forecast to 2030- Product Image
Sale

COX-2 Selective NSAIDs Market by Route, Dosage Form, Product, Indication, Distribution Channel, End User - Global Forecast to 2030

  • PDF Icon

    Report

  • 197 Pages
  • May 2025
  • Region: Global
  • 360iResearch™
  • ID: 6011575
UP TO OFF until Dec 31st 2025
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The COX-2 Selective NSAIDs Market grew from USD 8.19 billion in 2024 to USD 8.66 billion in 2025. It is expected to continue growing at a CAGR of 5.56%, reaching USD 11.34 billion by 2030.

Setting the Stage for the COX-2 Selective NSAIDs Landscape

The landscape of COX-2 selective nonsteroidal anti-inflammatory drugs (NSAIDs) stands at an inflection point, as evolving patient needs, regulatory frameworks, and technological advancements converge to redefine prescription pain management. This report opens by situating stakeholders within the current milieu of COX-2 inhibitors, exploring the historical emergence of these targeted therapies alongside traditional NSAIDs. With cardiovascular safety concerns and gastrointestinal tolerability driving the original shift toward selectivity, the industry now confronts a broader array of clinical imperatives and competitive pressures.

As healthcare systems worldwide prioritize value-based care, COX-2 selective agents are subject to renewed scrutiny around cost, efficacy, and long-term safety. Drug developers are racing to refine molecular profiles while payers demand robust evidence of differentiated outcomes. Concurrently, patients wield greater influence over treatment decisions, propelled by digital resources and personalized health platforms. By outlining these converging forces, the introduction lays the groundwork for a thorough examination of how manufacturers, clinicians, and policymakers must adapt to sustain growth and deliver improved patient experiences.

Emerging Forces Reshaping the COX-2 Selective NSAIDs Market

In recent years, a series of transformative shifts have realigned strategic priorities across the COX-2 selective NSAIDs domain. Precision medicine initiatives now emphasize patient stratification based on genetic markers and comorbidities, prompting targeted trials that go beyond broad safety and efficacy measures. Simultaneously, the digital health revolution infuses real-time data capture into post-marketing surveillance, enabling rapid identification of adverse events and adherence patterns.

Regulatory bodies have responded by streamlining approval pathways for novel formulations while reinforcing pharmacovigilance requirements for existing compounds. Generic competition continues to intensify, driving parallel efforts in formulation innovation and life-cycle management. At the same time, the integration of artificial intelligence in drug discovery accelerates lead optimization, reinforcing the importance of R&D agility. Collectively, these disruptive trends underscore a new era in which therapeutic differentiation hinges on evidence generation, digital integration, and adaptive commercialization models.

Assessing Tariff-Driven Dynamics in the US COX-2 NSAIDs Sector

The introduction of targeted tariffs on pharmaceutical imports in 2025 has injected fresh complexity into COX-2 selective NSAIDs supply chains, compelling manufacturers to reassess procurement, production, and pricing strategies. Raw material sourcing has shifted toward diversified geographic partners, with a notable pivot away from traditionally dominant low-cost regions. These realignments carry implications for manufacturing lead times, quality control protocols, and cost pass-through to end users.

Across domestic markets, payers and healthcare providers face amplified scrutiny of drug expenditures, prompting intensified negotiations over rebates and contracting terms. For multinationals exporting finished products, balancing tariff-induced cost increases against competitive pricing pressures in the hospital and retail pharmacy segments demands granular scenario planning. As a result, companies are forging strategic alliances with regional manufacturers, investing in localized manufacturing capacities, and leveraging free-trade agreements to mitigate the financial impact of new trade measures.

Unpacking Multifaceted Segments Driving Market Nuances

Unraveling market behavior requires a nuanced understanding of how administration route preferences influence prescribing patterns. Injectable formulations, valued for immediate therapeutic effect in acute care settings, compete with oral tablets that offer convenience and well-established dosing regimens. Topical applications, meanwhile, appeal to patients seeking localized relief with reduced systemic exposure. In parallel, the choice between capsules, suspensions, and tablets shapes patient adherence and physician recommendations, as differences in release profiles cater to diverse symptom management needs.

Further granularity emerges when examining the product portfolio itself. Legacy molecules such as celecoxib maintain a strong foothold in osteoarthritis management, while alternatives like etoricoxib and rofecoxib draw attention for their distinct pharmacokinetic properties. Valdecoxib’s historical withdrawal has spurred discourse on risk-benefit optimization in new analogs. These product-specific dynamics intersect with therapeutic indications, as clinicians tailor regimens for ankylosing spondylitis, rheumatoid arthritis, and chronic osteoarthritic pain, balancing efficacy against safety considerations.

Distribution channels add yet another layer of complexity, with hospital pharmacies serving high-acuity environments, online pharmacies providing direct manufacturer fulfillment and third-party retailing, and brick-and-mortar outlets-both chain and independent-commanding broad patient reach. On the demand side, clinics subdivided into outpatient and specialty settings interface with homecare providers and hospitals, whether public or private. Each end-user segment presents unique requirements around ordering cycles, cold chain logistics, digital ordering platforms, and formulary inclusion policies.

Distinct Regional Trends from Americas to Asia-Pacific

Regional dynamics shape the adoption and commercialization of COX-2 selective NSAIDs in markedly different ways. In the Americas, the United States leads in clinical research investment and formulary negotiations, while Brazil and Canada focus on expanding public healthcare access and integrating generics into national reimbursement schemes. The regulatory rigor in North America underscores a growing emphasis on real-world evidence and comparative effectiveness studies to validate premium pricing.

Across Europe, Middle East & Africa, heterogeneous healthcare frameworks drive disparate uptake rates. Western European markets rely on centralized health technology assessments to guide coverage, whereas emerging economies in the Middle East and Africa contend with infrastructural constraints and variable regulatory harmonization. This patchwork landscape offers opportunities for targeted market entry strategies that leverage public-private partnerships and capacity-building initiatives.

In Asia-Pacific, rapid urbanization and increasing healthcare spending propel market expansion. Japan and Australia uphold stringent safety assessments, while China’s evolving patent landscape and India’s robust generic manufacturing capabilities introduce competitive dynamics. Cross-border collaborations, tech-enabled distribution models, and tiered pricing schemes play pivotal roles in aligning therapy access with economic diversity across the region.

Competitive Strategies of Leading COX-2 NSAIDs Developers

The competitive battleground for COX-2 selective NSAIDs is dominated by firms investing in differentiated formulations, robust safety data, and targeted marketing outreach. Established pharmaceutical leaders focus on extending product life cycles through novel delivery mechanisms, such as extended-release tablets or combination therapies that pair COX-2 inhibitors with gastroprotective agents. Smaller biotech players seek to carve niche positions by advancing proprietary analogs or leveraging partnerships for global distribution.

Strategic alliances have become commonplace as companies pool resources to conduct head-to-head clinical trials and co-market products in regions with complex regulatory requirements. Concurrently, intellectual property strategies emphasize patent term extensions and geographic exclusivities to safeguard market share against generic erosion. In digital channels, direct-to-patient engagement platforms designed by forward-thinking competitors enhance patient education and adherence monitoring, setting a new standard for end-to-end brand loyalty.

Strategic Imperatives for Capturing COX-2 NSAIDs Market Opportunities

To capitalize on emerging opportunities in the COX-2 selective NSAIDs arena, stakeholders should prioritize a multi-pronged approach centered on innovation, collaboration, and patient engagement. Pipeline diversification is essential: investing in next-generation selective inhibitors with enhanced safety profiles can secure differentiation even as generics proliferate. Complementary digital health solutions-ranging from telemedicine support to adherence tracking apps-can deepen patient insights and foster long-term brand allegiance.

Supply chain resilience must also be reinforced through geographic diversification of raw material sources and strategic partnerships with contract manufacturers. Adopting flexible pricing models that reflect value demonstrated in real-world outcomes can align stakeholders across hospital, clinic, and homecare settings. Moreover, engaging early with regulatory authorities to shape pharmacovigilance frameworks and streamline approval processes will reduce time to market and reinforce credibility with payers.

Rigorous Analytical Framework Underpinning Our Findings

Our methodology integrates rigorous primary and secondary research streams to ensure comprehensive, unbiased insights. Primary research involved in-depth interviews with key opinion leaders, regulatory agency representatives, and supply chain executives across major geographic markets. This qualitative input was complemented by targeted surveys of prescribing physicians and patient focus groups to capture real-world usage patterns and unmet needs.

Secondary research encompassed extensive analysis of public filings, clinical registries, patent databases, and health technology assessment reports. Quantitative data were triangulated with proprietary innovation trackers and real-world evidence platforms to validate market dynamics. Throughout the process, quality assurance protocols, including peer review by independent experts and cross-validation of findings, safeguarded the integrity of our conclusions. This blended approach ensures that stakeholders receive robust, actionable intelligence grounded in both empirical data and frontline perspectives.

Converging Insights and Future Pathways

The confluence of shifting therapeutic paradigms, regulatory evolution, and market segmentation underscores the dynamic character of the COX-2 selective NSAIDs industry. Key takeaways include the imperative to balance molecular innovation with real-world evidence generation, the strategic necessity of multi-channel distribution optimization, and the growing influence of tariff policies on supply chain decisions.

Looking ahead, stakeholders equipped with granular insights across administration routes, dosage forms, product portfolios, regional landscapes, and competitive tactics will be best positioned to navigate uncertainty. By synthesizing these core elements, organizations can chart robust strategies that drive sustainable growth, bolster patient outcomes, and maintain regulatory compliance. Ultimately, the integration of evidence-based planning with adaptive execution will define the next frontier of success in this rapidly evolving market.

Market Segmentation & Coverage

This research report categorizes to forecast the revenues and analyze trends in each of the following sub-segmentations:
  • Route
    • Injectable
    • Oral
    • Topical
  • Dosage Form
    • Capsule
    • Suspension
    • Tablet
  • Product
    • Celecoxib
    • Etoricoxib
    • Rofecoxib
    • Valdecoxib
  • Indication
    • Ankylosing Spondylitis
    • Osteoarthritis
    • Rheumatoid Arthritis
  • Distribution Channel
    • Hospital Pharmacy
    • Online Pharmacy
      • Direct Manufacturer
      • Third-Party ERetailers
    • Retail Pharmacy
      • Chain Pharmacy
      • Independent Pharmacy
  • End User
    • Clinics
      • Outpatient Clinics
      • Specialty Clinics
    • Homecare
    • Hospitals
      • Private
      • Public
This research report categorizes to forecast the revenues and analyze trends in each of the following sub-regions:
  • Americas
    • United States
      • California
      • Texas
      • New York
      • Florida
      • Illinois
      • Pennsylvania
      • Ohio
    • Canada
    • Mexico
    • Brazil
    • Argentina
  • Europe, Middle East & Africa
    • United Kingdom
    • Germany
    • France
    • Russia
    • Italy
    • Spain
    • United Arab Emirates
    • Saudi Arabia
    • South Africa
    • Denmark
    • Netherlands
    • Qatar
    • Finland
    • Sweden
    • Nigeria
    • Egypt
    • Turkey
    • Israel
    • Norway
    • Poland
    • Switzerland
  • Asia-Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
    • Indonesia
    • Thailand
    • Philippines
    • Malaysia
    • Singapore
    • Vietnam
    • Taiwan
This research report categorizes to delves into recent significant developments and analyze trends in each of the following companies:
  • Pfizer Inc.
  • Merck & Co., Inc.
  • Novartis AG
  • Teva Pharmaceutical Industries Ltd.
  • Sandoz International GmbH
  • Dr. Reddy's Laboratories Ltd.
  • Lupin Limited

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Market Sizing & Forecasting
5. Market Dynamics
6. Market Insights
6.1. Porter’s Five Forces Analysis
6.2. PESTLE Analysis
7. Cumulative Impact of United States Tariffs 2025
8. COX-2 Selective NSAIDs Market, by Route
8.1. Introduction
8.2. Injectable
8.3. Oral
8.4. Topical
9. COX-2 Selective NSAIDs Market, by Dosage Form
9.1. Introduction
9.2. Capsule
9.3. Suspension
9.4. Tablet
10. COX-2 Selective NSAIDs Market, by Product
10.1. Introduction
10.2. Celecoxib
10.3. Etoricoxib
10.4. Rofecoxib
10.5. Valdecoxib
11. COX-2 Selective NSAIDs Market, by Indication
11.1. Introduction
11.2. Ankylosing Spondylitis
11.3. Osteoarthritis
11.4. Rheumatoid Arthritis
12. COX-2 Selective NSAIDs Market, by Distribution Channel
12.1. Introduction
12.2. Hospital Pharmacy
12.3. Online Pharmacy
12.3.1. Direct Manufacturer
12.3.2. Third-Party ERetailers
12.4. Retail Pharmacy
12.4.1. Chain Pharmacy
12.4.2. Independent Pharmacy
13. COX-2 Selective NSAIDs Market, by End User
13.1. Introduction
13.2. Clinics
13.2.1. Outpatient Clinics
13.2.2. Specialty Clinics
13.3. Homecare
13.4. Hospitals
13.4.1. Private
13.4.2. Public
14. Americas COX-2 Selective NSAIDs Market
14.1. Introduction
14.2. United States
14.3. Canada
14.4. Mexico
14.5. Brazil
14.6. Argentina
15. Europe, Middle East & Africa COX-2 Selective NSAIDs Market
15.1. Introduction
15.2. United Kingdom
15.3. Germany
15.4. France
15.5. Russia
15.6. Italy
15.7. Spain
15.8. United Arab Emirates
15.9. Saudi Arabia
15.10. South Africa
15.11. Denmark
15.12. Netherlands
15.13. Qatar
15.14. Finland
15.15. Sweden
15.16. Nigeria
15.17. Egypt
15.18. Turkey
15.19. Israel
15.20. Norway
15.21. Poland
15.22. Switzerland
16. Asia-Pacific COX-2 Selective NSAIDs Market
16.1. Introduction
16.2. China
16.3. India
16.4. Japan
16.5. Australia
16.6. South Korea
16.7. Indonesia
16.8. Thailand
16.9. Philippines
16.10. Malaysia
16.11. Singapore
16.12. Vietnam
16.13. Taiwan
17. Competitive Landscape
17.1. Market Share Analysis, 2024
17.2. FPNV Positioning Matrix, 2024
17.3. Competitive Analysis
17.3.1. Pfizer Inc.
17.3.2. Merck & Co., Inc.
17.3.3. Novartis AG
17.3.4. Teva Pharmaceutical Industries Ltd.
17.3.5. Sandoz International GmbH
17.3.6. Dr. Reddy's Laboratories Ltd.
17.3.7. Lupin Limited
18. ResearchAI
19. ResearchStatistics
20. ResearchContacts
21. ResearchArticles
22. Appendix
List of Figures
FIGURE 1. COX-2 SELECTIVE NSAIDS MARKET MULTI-CURRENCY
FIGURE 2. COX-2 SELECTIVE NSAIDS MARKET MULTI-LANGUAGE
FIGURE 3. COX-2 SELECTIVE NSAIDS MARKET RESEARCH PROCESS
FIGURE 4. GLOBAL COX-2 SELECTIVE NSAIDS MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 5. GLOBAL COX-2 SELECTIVE NSAIDS MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 6. GLOBAL COX-2 SELECTIVE NSAIDS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 7. GLOBAL COX-2 SELECTIVE NSAIDS MARKET SIZE, BY ROUTE, 2024 VS 2030 (%)
FIGURE 8. GLOBAL COX-2 SELECTIVE NSAIDS MARKET SIZE, BY ROUTE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL COX-2 SELECTIVE NSAIDS MARKET SIZE, BY DOSAGE FORM, 2024 VS 2030 (%)
FIGURE 10. GLOBAL COX-2 SELECTIVE NSAIDS MARKET SIZE, BY DOSAGE FORM, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 11. GLOBAL COX-2 SELECTIVE NSAIDS MARKET SIZE, BY PRODUCT, 2024 VS 2030 (%)
FIGURE 12. GLOBAL COX-2 SELECTIVE NSAIDS MARKET SIZE, BY PRODUCT, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 13. GLOBAL COX-2 SELECTIVE NSAIDS MARKET SIZE, BY INDICATION, 2024 VS 2030 (%)
FIGURE 14. GLOBAL COX-2 SELECTIVE NSAIDS MARKET SIZE, BY INDICATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 15. GLOBAL COX-2 SELECTIVE NSAIDS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2030 (%)
FIGURE 16. GLOBAL COX-2 SELECTIVE NSAIDS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 17. GLOBAL COX-2 SELECTIVE NSAIDS MARKET SIZE, BY END USER, 2024 VS 2030 (%)
FIGURE 18. GLOBAL COX-2 SELECTIVE NSAIDS MARKET SIZE, BY END USER, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 19. AMERICAS COX-2 SELECTIVE NSAIDS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 20. AMERICAS COX-2 SELECTIVE NSAIDS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 21. UNITED STATES COX-2 SELECTIVE NSAIDS MARKET SIZE, BY STATE, 2024 VS 2030 (%)
FIGURE 22. UNITED STATES COX-2 SELECTIVE NSAIDS MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 23. EUROPE, MIDDLE EAST & AFRICA COX-2 SELECTIVE NSAIDS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 24. EUROPE, MIDDLE EAST & AFRICA COX-2 SELECTIVE NSAIDS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 25. ASIA-PACIFIC COX-2 SELECTIVE NSAIDS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 26. ASIA-PACIFIC COX-2 SELECTIVE NSAIDS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 27. COX-2 SELECTIVE NSAIDS MARKET SHARE, BY KEY PLAYER, 2024
FIGURE 28. COX-2 SELECTIVE NSAIDS MARKET, FPNV POSITIONING MATRIX, 2024
List of Tables
TABLE 1. COX-2 SELECTIVE NSAIDS MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
TABLE 3. GLOBAL COX-2 SELECTIVE NSAIDS MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 4. GLOBAL COX-2 SELECTIVE NSAIDS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
TABLE 5. GLOBAL COX-2 SELECTIVE NSAIDS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 6. GLOBAL COX-2 SELECTIVE NSAIDS MARKET SIZE, BY ROUTE, 2018-2030 (USD MILLION)
TABLE 7. GLOBAL COX-2 SELECTIVE NSAIDS MARKET SIZE, BY INJECTABLE, BY REGION, 2018-2030 (USD MILLION)
TABLE 8. GLOBAL COX-2 SELECTIVE NSAIDS MARKET SIZE, BY ORAL, BY REGION, 2018-2030 (USD MILLION)
TABLE 9. GLOBAL COX-2 SELECTIVE NSAIDS MARKET SIZE, BY TOPICAL, BY REGION, 2018-2030 (USD MILLION)
TABLE 10. GLOBAL COX-2 SELECTIVE NSAIDS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 11. GLOBAL COX-2 SELECTIVE NSAIDS MARKET SIZE, BY CAPSULE, BY REGION, 2018-2030 (USD MILLION)
TABLE 12. GLOBAL COX-2 SELECTIVE NSAIDS MARKET SIZE, BY SUSPENSION, BY REGION, 2018-2030 (USD MILLION)
TABLE 13. GLOBAL COX-2 SELECTIVE NSAIDS MARKET SIZE, BY TABLET, BY REGION, 2018-2030 (USD MILLION)
TABLE 14. GLOBAL COX-2 SELECTIVE NSAIDS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 15. GLOBAL COX-2 SELECTIVE NSAIDS MARKET SIZE, BY CELECOXIB, BY REGION, 2018-2030 (USD MILLION)
TABLE 16. GLOBAL COX-2 SELECTIVE NSAIDS MARKET SIZE, BY ETORICOXIB, BY REGION, 2018-2030 (USD MILLION)
TABLE 17. GLOBAL COX-2 SELECTIVE NSAIDS MARKET SIZE, BY ROFECOXIB, BY REGION, 2018-2030 (USD MILLION)
TABLE 18. GLOBAL COX-2 SELECTIVE NSAIDS MARKET SIZE, BY VALDECOXIB, BY REGION, 2018-2030 (USD MILLION)
TABLE 19. GLOBAL COX-2 SELECTIVE NSAIDS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 20. GLOBAL COX-2 SELECTIVE NSAIDS MARKET SIZE, BY ANKYLOSING SPONDYLITIS, BY REGION, 2018-2030 (USD MILLION)
TABLE 21. GLOBAL COX-2 SELECTIVE NSAIDS MARKET SIZE, BY OSTEOARTHRITIS, BY REGION, 2018-2030 (USD MILLION)
TABLE 22. GLOBAL COX-2 SELECTIVE NSAIDS MARKET SIZE, BY RHEUMATOID ARTHRITIS, BY REGION, 2018-2030 (USD MILLION)
TABLE 23. GLOBAL COX-2 SELECTIVE NSAIDS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 24. GLOBAL COX-2 SELECTIVE NSAIDS MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2018-2030 (USD MILLION)
TABLE 25. GLOBAL COX-2 SELECTIVE NSAIDS MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2018-2030 (USD MILLION)
TABLE 26. GLOBAL COX-2 SELECTIVE NSAIDS MARKET SIZE, BY DIRECT MANUFACTURER, BY REGION, 2018-2030 (USD MILLION)
TABLE 27. GLOBAL COX-2 SELECTIVE NSAIDS MARKET SIZE, BY THIRD-PARTY ERETAILERS, BY REGION, 2018-2030 (USD MILLION)
TABLE 28. GLOBAL COX-2 SELECTIVE NSAIDS MARKET SIZE, BY ONLINE PHARMACY, 2018-2030 (USD MILLION)
TABLE 29. GLOBAL COX-2 SELECTIVE NSAIDS MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2018-2030 (USD MILLION)
TABLE 30. GLOBAL COX-2 SELECTIVE NSAIDS MARKET SIZE, BY CHAIN PHARMACY, BY REGION, 2018-2030 (USD MILLION)
TABLE 31. GLOBAL COX-2 SELECTIVE NSAIDS MARKET SIZE, BY INDEPENDENT PHARMACY, BY REGION, 2018-2030 (USD MILLION)
TABLE 32. GLOBAL COX-2 SELECTIVE NSAIDS MARKET SIZE, BY RETAIL PHARMACY, 2018-2030 (USD MILLION)
TABLE 33. GLOBAL COX-2 SELECTIVE NSAIDS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 34. GLOBAL COX-2 SELECTIVE NSAIDS MARKET SIZE, BY CLINICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 35. GLOBAL COX-2 SELECTIVE NSAIDS MARKET SIZE, BY OUTPATIENT CLINICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 36. GLOBAL COX-2 SELECTIVE NSAIDS MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 37. GLOBAL COX-2 SELECTIVE NSAIDS MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 38. GLOBAL COX-2 SELECTIVE NSAIDS MARKET SIZE, BY HOMECARE, BY REGION, 2018-2030 (USD MILLION)
TABLE 39. GLOBAL COX-2 SELECTIVE NSAIDS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
TABLE 40. GLOBAL COX-2 SELECTIVE NSAIDS MARKET SIZE, BY PRIVATE, BY REGION, 2018-2030 (USD MILLION)
TABLE 41. GLOBAL COX-2 SELECTIVE NSAIDS MARKET SIZE, BY PUBLIC, BY REGION, 2018-2030 (USD MILLION)
TABLE 42. GLOBAL COX-2 SELECTIVE NSAIDS MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 43. AMERICAS COX-2 SELECTIVE NSAIDS MARKET SIZE, BY ROUTE, 2018-2030 (USD MILLION)
TABLE 44. AMERICAS COX-2 SELECTIVE NSAIDS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 45. AMERICAS COX-2 SELECTIVE NSAIDS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 46. AMERICAS COX-2 SELECTIVE NSAIDS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 47. AMERICAS COX-2 SELECTIVE NSAIDS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 48. AMERICAS COX-2 SELECTIVE NSAIDS MARKET SIZE, BY ONLINE PHARMACY, 2018-2030 (USD MILLION)
TABLE 49. AMERICAS COX-2 SELECTIVE NSAIDS MARKET SIZE, BY RETAIL PHARMACY, 2018-2030 (USD MILLION)
TABLE 50. AMERICAS COX-2 SELECTIVE NSAIDS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 51. AMERICAS COX-2 SELECTIVE NSAIDS MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 52. AMERICAS COX-2 SELECTIVE NSAIDS MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 53. AMERICAS COX-2 SELECTIVE NSAIDS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 54. UNITED STATES COX-2 SELECTIVE NSAIDS MARKET SIZE, BY ROUTE, 2018-2030 (USD MILLION)
TABLE 55. UNITED STATES COX-2 SELECTIVE NSAIDS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 56. UNITED STATES COX-2 SELECTIVE NSAIDS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 57. UNITED STATES COX-2 SELECTIVE NSAIDS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 58. UNITED STATES COX-2 SELECTIVE NSAIDS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 59. UNITED STATES COX-2 SELECTIVE NSAIDS MARKET SIZE, BY ONLINE PHARMACY, 2018-2030 (USD MILLION)
TABLE 60. UNITED STATES COX-2 SELECTIVE NSAIDS MARKET SIZE, BY RETAIL PHARMACY, 2018-2030 (USD MILLION)
TABLE 61. UNITED STATES COX-2 SELECTIVE NSAIDS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 62. UNITED STATES COX-2 SELECTIVE NSAIDS MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 63. UNITED STATES COX-2 SELECTIVE NSAIDS MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 64. UNITED STATES COX-2 SELECTIVE NSAIDS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
TABLE 65. CANADA COX-2 SELECTIVE NSAIDS MARKET SIZE, BY ROUTE, 2018-2030 (USD MILLION)
TABLE 66. CANADA COX-2 SELECTIVE NSAIDS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 67. CANADA COX-2 SELECTIVE NSAIDS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 68. CANADA COX-2 SELECTIVE NSAIDS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 69. CANADA COX-2 SELECTIVE NSAIDS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 70. CANADA COX-2 SELECTIVE NSAIDS MARKET SIZE, BY ONLINE PHARMACY, 2018-2030 (USD MILLION)
TABLE 71. CANADA COX-2 SELECTIVE NSAIDS MARKET SIZE, BY RETAIL PHARMACY, 2018-2030 (USD MILLION)
TABLE 72. CANADA COX-2 SELECTIVE NSAIDS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 73. CANADA COX-2 SELECTIVE NSAIDS MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 74. CANADA COX-2 SELECTIVE NSAIDS MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 75. MEXICO COX-2 SELECTIVE NSAIDS MARKET SIZE, BY ROUTE, 2018-2030 (USD MILLION)
TABLE 76. MEXICO COX-2 SELECTIVE NSAIDS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 77. MEXICO COX-2 SELECTIVE NSAIDS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 78. MEXICO COX-2 SELECTIVE NSAIDS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 79. MEXICO COX-2 SELECTIVE NSAIDS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 80. MEXICO COX-2 SELECTIVE NSAIDS MARKET SIZE, BY ONLINE PHARMACY, 2018-2030 (USD MILLION)
TABLE 81. MEXICO COX-2 SELECTIVE NSAIDS MARKET SIZE, BY RETAIL PHARMACY, 2018-2030 (USD MILLION)
TABLE 82. MEXICO COX-2 SELECTIVE NSAIDS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 83. MEXICO COX-2 SELECTIVE NSAIDS MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 84. MEXICO COX-2 SELECTIVE NSAIDS MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 85. BRAZIL COX-2 SELECTIVE NSAIDS MARKET SIZE, BY ROUTE, 2018-2030 (USD MILLION)
TABLE 86. BRAZIL COX-2 SELECTIVE NSAIDS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 87. BRAZIL COX-2 SELECTIVE NSAIDS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 88. BRAZIL COX-2 SELECTIVE NSAIDS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 89. BRAZIL COX-2 SELECTIVE NSAIDS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 90. BRAZIL COX-2 SELECTIVE NSAIDS MARKET SIZE, BY ONLINE PHARMACY, 2018-2030 (USD MILLION)
TABLE 91. BRAZIL COX-2 SELECTIVE NSAIDS MARKET SIZE, BY RETAIL PHARMACY, 2018-2030 (USD MILLION)
TABLE 92. BRAZIL COX-2 SELECTIVE NSAIDS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 93. BRAZIL COX-2 SELECTIVE NSAIDS MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 94. BRAZIL COX-2 SELECTIVE NSAIDS MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 95. ARGENTINA COX-2 SELECTIVE NSAIDS MARKET SIZE, BY ROUTE, 2018-2030 (USD MILLION)
TABLE 96. ARGENTINA COX-2 SELECTIVE NSAIDS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 97. ARGENTINA COX-2 SELECTIVE NSAIDS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 98. ARGENTINA COX-2 SELECTIVE NSAIDS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 99. ARGENTINA COX-2 SELECTIVE NSAIDS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 100. ARGENTINA COX-2 SELECTIVE NSAIDS MARKET SIZE, BY ONLINE PHARMACY, 2018-2030 (USD MILLION)
TABLE 101. ARGENTINA COX-2 SELECTIVE NSAIDS MARKET SIZE, BY RETAIL PHARMACY, 2018-2030 (USD MILLION)
TABLE 102. ARGENTINA COX-2 SELECTIVE NSAIDS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 103. ARGENTINA COX-2 SELECTIVE NSAIDS MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 104. ARGENTINA COX-2 SELECTIVE NSAIDS MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 105. EUROPE, MIDDLE EAST & AFRICA COX-2 SELECTIVE NSAIDS MARKET SIZE, BY ROUTE, 2018-2030 (USD MILLION)
TABLE 106. EUROPE, MIDDLE EAST & AFRICA COX-2 SELECTIVE NSAIDS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 107. EUROPE, MIDDLE EAST & AFRICA COX-2 SELECTIVE NSAIDS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 108. EUROPE, MIDDLE EAST & AFRICA COX-2 SELECTIVE NSAIDS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 109. EUROPE, MIDDLE EAST & AFRICA COX-2 SELECTIVE NSAIDS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 110. EUROPE, MIDDLE EAST & AFRICA COX-2 SELECTIVE NSAIDS MARKET SIZE, BY ONLINE PHARMACY, 2018-2030 (USD MILLION)
TABLE 111. EUROPE, MIDDLE EAST & AFRICA COX-2 SELECTIVE NSAIDS MARKET SIZE, BY RETAIL PHARMACY, 2018-2030 (USD MILLION)
TABLE 112. EUROPE, MIDDLE EAST & AFRICA COX-2 SELECTIVE NSAIDS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 113. EUROPE, MIDDLE EAST & AFRICA COX-2 SELECTIVE NSAIDS MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 114. EUROPE, MIDDLE EAST & AFRICA COX-2 SELECTIVE NSAIDS MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 115. EUROPE, MIDDLE EAST & AFRICA COX-2 SELECTIVE NSAIDS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 116. UNITED KINGDOM COX-2 SELECTIVE NSAIDS MARKET SIZE, BY ROUTE, 2018-2030 (USD MILLION)
TABLE 117. UNITED KINGDOM COX-2 SELECTIVE NSAIDS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 118. UNITED KINGDOM COX-2 SELECTIVE NSAIDS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 119. UNITED KINGDOM COX-2 SELECTIVE NSAIDS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 120. UNITED KINGDOM COX-2 SELECTIVE NSAIDS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 121. UNITED KINGDOM COX-2 SELECTIVE NSAIDS MARKET SIZE, BY ONLINE PHARMACY, 2018-2030 (USD MILLION)
TABLE 122. UNITED KINGDOM COX-2 SELECTIVE NSAIDS MARKET SIZE, BY RETAIL PHARMACY, 2018-2030 (USD MILLION)
TABLE 123. UNITED KINGDOM COX-2 SELECTIVE NSAIDS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 124. UNITED KINGDOM COX-2 SELECTIVE NSAIDS MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 125. UNITED KINGDOM COX-2 SELECTIVE NSAIDS MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 126. GERMANY COX-2 SELECTIVE NSAIDS MARKET SIZE, BY ROUTE, 2018-2030 (USD MILLION)
TABLE 127. GERMANY COX-2 SELECTIVE NSAIDS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 128. GERMANY COX-2 SELECTIVE NSAIDS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 129. GERMANY COX-2 SELECTIVE NSAIDS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 130. GERMANY COX-2 SELECTIVE NSAIDS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 131. GERMANY COX-2 SELECTIVE NSAIDS MARKET SIZE, BY ONLINE PHARMACY, 2018-2030 (USD MILLION)
TABLE 132. GERMANY COX-2 SELECTIVE NSAIDS MARKET SIZE, BY RETAIL PHARMACY, 2018-2030 (USD MILLION)
TABLE 133. GERMANY COX-2 SELECTIVE NSAIDS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 134. GERMANY COX-2 SELECTIVE NSAIDS MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 135. GERMANY COX-2 SELECTIVE NSAIDS MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 136. FRANCE COX-2 SELECTIVE NSAIDS MARKET SIZE, BY ROUTE, 2018-2030 (USD MILLION)
TABLE 137. FRANCE COX-2 SELECTIVE NSAIDS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 138. FRANCE COX-2 SELECTIVE NSAIDS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 139. FRANCE COX-2 SELECTIVE NSAIDS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 140. FRANCE COX-2 SELECTIVE NSAIDS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 141. FRANCE COX-2 SELECTIVE NSAIDS MARKET SIZE, BY ONLINE PHARMACY, 2018-2030 (USD MILLION)
TABLE 142. FRANCE COX-2 SELECTIVE NSAIDS MARKET SIZE, BY RETAIL PHARMACY, 2018-2030 (USD MILLION)
TABLE 143. FRANCE COX-2 SELECTIVE NSAIDS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 144. FRANCE COX-2 SELECTIVE NSAIDS MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 145. FRANCE COX-2 SELECTIVE NSAIDS MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 146. RUSSIA COX-2 SELECTIVE NSAIDS MARKET SIZE, BY ROUTE, 2018-2030 (USD MILLION)
TABLE 147. RUSSIA COX-2 SELECTIVE NSAIDS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 148. RUSSIA COX-2 SELECTIVE NSAIDS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 149. RUSSIA COX-2 SELECTIVE NSAIDS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 150. RUSSIA COX-2 SELECTIVE NSAIDS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 151. RUSSIA COX-2 SELECTIVE NSAIDS MARKET SIZE, BY ONLINE PHARMACY, 2018-2030 (USD MILLION)
TABLE 152. RUSSIA COX-2 SELECTIVE NSAIDS MARKET SIZE, BY RETAIL PHARMACY, 2018-2030 (USD MILLION)
TABLE 153. RUSSIA COX-2 SELECTIVE NSAIDS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 154. RUSSIA COX-2 SELECTIVE NSAIDS MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 155. RUSSIA COX-2 SELECTIVE NSAIDS MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 156. ITALY COX-2 SELECTIVE NSAIDS MARKET SIZE, BY ROUTE, 2018-2030 (USD MILLION)
TABLE 157. ITALY COX-2 SELECTIVE NSAIDS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 158. ITALY COX-2 SELECTIVE NSAIDS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 159. ITALY COX-2 SELECTIVE NSAIDS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 160. ITALY COX-2 SELECTIVE NSAIDS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 161. ITALY COX-2 SELECTIVE NSAIDS MARKET SIZE, BY ONLINE PHARMACY, 2018-2030 (USD MILLION)
TABLE 162. ITALY COX-2 SELECTIVE NSAIDS MARKET SIZE, BY RETAIL PHARMACY, 2018-2030 (USD MILLION)
TABLE 163. ITALY COX-2 SELECTIVE NSAIDS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 164. ITALY COX-2 SELECTIVE NSAIDS MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 165. ITALY COX-2 SELECTIVE NSAIDS MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 166. SPAIN COX-2 SELECTIVE NSAIDS MARKET SIZE, BY ROUTE, 2018-2030 (USD MILLION)
TABLE 167. SPAIN COX-2 SELECTIVE NSAIDS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 168. SPAIN COX-2 SELECTIVE NSAIDS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 169. SPAIN COX-2 SELECTIVE NSAIDS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 170. SPAIN COX-2 SELECTIVE NSAIDS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 171. SPAIN COX-2 SELECTIVE NSAIDS MARKET SIZE, BY ONLINE PHARMACY, 2018-2030 (USD MILLION)
TABLE 172. SPAIN COX-2 SELECTIVE NSAIDS MARKET SIZE, BY RETAIL PHARMACY, 2018-2030 (USD MILLION)
TABLE 173. SPAIN COX-2 SELECTIVE NSAIDS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 174. SPAIN COX-2 SELECTIVE NSAIDS MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 175. SPAIN COX-2 SELECTIVE NSAIDS MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 176. UNITED ARAB EMIRATES COX-2 SELECTIVE NSAIDS MARKET SIZE, BY ROUTE, 2018-2030 (USD MILLION)
TABLE 177. UNITED ARAB EMIRATES COX-2 SELECTIVE NSAIDS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 178. UNITED ARAB EMIRATES COX-2 SELECTIVE NSAIDS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 179. UNITED ARAB EMIRATES COX-2 SELECTIVE NSAIDS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 180. UNITED ARAB EMIRATES COX-2 SELECTIVE NSAIDS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 181. UNITED ARAB EMIRATES COX-2 SELECTIVE NSAIDS MARKET SIZE, BY ONLINE PHARMACY, 2018-2030 (USD MILLION)
TABLE 182. UNITED ARAB EMIRATES COX-2 SELECTIVE NSAIDS MARKET SIZE, BY RETAIL PHARMACY, 2018-2030 (USD MILLION)
TABLE 183. UNITED ARAB EMIRATES COX-2 SELECTIVE NSAIDS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 184. UNITED ARAB EMIRATES COX-2 SELECTIVE NSAIDS MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 185. UNITED ARAB EMIRATES COX-2 SELECTIVE NSAIDS MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 186. SAUDI ARABIA COX-2 SELECTIVE NSAIDS MARKET SIZE, BY ROUTE, 2018-2030 (USD MILLION)
TABLE 187. SAUDI ARABIA COX-2 SELECTIVE NSAIDS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 188. SAUDI ARABIA COX-2 SELECTIVE NSAIDS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 189. SAUDI ARABIA COX-2 SELECTIVE NSAIDS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 190. SAUDI ARABIA COX-2 SELECTIVE NSAIDS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 191. SAUDI ARABIA COX-2 SELECTIVE NSAIDS MARKET SIZE, BY ONLINE PHARMACY, 2018-2030 (USD MILLION)
TABLE 192. SAUDI ARABIA COX-2 SELECTIVE NSAIDS MARKET SIZE, BY RETAIL PHARMACY, 2018-2030 (USD MILLION)
TABLE 193. SAUDI ARABIA COX-2 SELECTIVE NSAIDS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 194. SAUDI ARABIA COX-2 SELECTIVE NSAIDS MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 195. SAUDI ARABIA COX-2 SELECTIVE NSAIDS MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 196. SOUTH AFRICA COX-2 SELECTIVE NSAIDS MARKET SIZE, BY ROUTE, 2018-2030 (USD MILLION)
TABLE 197. SOUTH AFRICA COX-2 SELECTIVE NSAIDS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 198. SOUTH AFRICA COX-2 SELECTIVE NSAIDS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 199. SOUTH AFRICA COX-2 SELECTIVE NSAIDS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 200. SOUTH AFRICA COX-2 SELECTIVE NSAIDS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 201. SOUTH AFRICA COX-2 SELECTIVE NSAIDS MARKET SIZE, BY ONLINE PHARMACY, 2018-2030 (USD MILLION)
TABLE 202. SOUTH AFRICA COX-2 SELECTIVE NSAIDS MARKET SIZE, BY RETAIL PHARMACY, 2018-2030 (USD MILLION)
TABLE 203. SOUTH AFRICA COX-2 SELECTIVE NSAIDS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 204. SOUTH AFRICA COX-2 SELECTIVE NSAIDS MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 205. SOUTH AFRICA COX-2 SELECTIVE NSAIDS MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 206. DENMARK COX-2 SELECTIVE NSAIDS MARKET SIZE, BY ROUTE, 2018-2030 (USD MILLION)
TABLE 207. DENMARK COX-2 SELECTIVE NSAIDS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 208. DENMARK COX-2 SELECTIVE NSAIDS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 209. DENMARK COX-2 SELECTIVE NSAIDS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 210. DENMARK COX-2 SELECTIVE NSAIDS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 211. DENMARK COX-2 SELECTIVE NSAIDS MARKET SIZE, BY ONLINE PHARMACY, 2018-2030 (USD MILLION)
TABLE 212. DENMARK COX-2 SELECTIVE NSAIDS MARKET SIZE, BY RETAIL PHARMACY, 2018-2030 (USD MILLION)
TABLE 213. DENMARK COX-2 SELECTIVE NSAIDS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 214. DENMARK COX-2 SELECTIVE NSAIDS MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 215. DENMARK COX-2 SELECTIVE NSAIDS MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 216. NETHERLANDS COX-2 SELECTIVE NSAIDS MARKET SIZE, BY ROUTE, 2018-2030 (USD MILLION)
TABLE 217. NETHERLANDS COX-2 SELECTIVE NSAIDS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 218. NETHERLANDS COX-2 SELECTIVE NSAIDS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 219. NETHERLANDS COX-2 SELECTIVE NSAIDS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 220. NETHERLANDS COX-2 SELECTIVE NSAIDS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 221. NETHERLANDS COX-2 SELECTIVE NSAIDS MARKET SIZE, BY ONLINE PHARMACY, 2018-2030 (USD MILLION)
TABLE 222. NETHERLANDS COX-2 SELECTIVE NSAIDS MARKET SIZE, BY RETAIL PHARMACY, 2018-2030 (USD MILLION)
TABLE 223. NETHERLANDS COX-2 SELECTIVE NSAIDS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 224. NETHERLANDS COX-2 SELECTIVE NSAIDS MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 225. NETHERLANDS COX-2 SELECTIVE NSAIDS MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 226. QATAR COX-2 SELECTIVE NSAIDS MARKET SIZE, BY ROUTE, 2018-2030 (USD MILLION)
TABLE 227. QATAR COX-2 SELECTIVE NSAIDS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 228. QATAR COX-2 SELECTIVE NSAIDS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 229. QATAR COX-2 SELECTIVE NSAIDS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 230. QATAR COX-2 SELECTIVE NSAIDS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 231. QATAR COX-2 SELECTIVE NSAIDS MARKET SIZE, BY ONLINE PHARMACY, 2018-2030 (USD MILLION)
TABLE 232. QATAR COX-2 SELECTIVE NSAIDS MARKET SIZE, BY RETAIL PHARMACY, 2018-2030 (USD MILLION)
TABLE 233. QATAR COX-2 SELECTIVE NSAIDS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 234. QATAR COX-2 SELECTIVE NSAIDS MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 235. QATAR COX-2 SELECTIVE NSAIDS MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 236. FINLAND COX-2 SELECTIVE NSAIDS MARKET SIZE, BY ROUTE, 2018-2030 (USD MILLION)
TABLE 237. FINLAND COX-2 SELECTIVE NSAIDS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 238. FINLAND COX-2 SELECTIVE NSAIDS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 239. FINLAND COX-2 SELECTIVE NSAIDS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 240. FINLAND COX-2 SELECTIVE NSAIDS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 241. FINLAND COX-2 SELECTIVE NSAIDS MARKET SIZE, BY ONLINE PHARMACY, 2018-2030 (USD MILLION)
TABLE 242. FINLAND COX-2 SELECTIVE NSAIDS MARKET SIZE, BY RETAIL PHARMACY, 2018-2030 (USD MILLION)
TABLE 243. FINLAND COX-2 SELECTIVE NSAIDS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 244. FINLAND COX-2 SELECTIVE NSAIDS MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 245. FINLAND COX-2 SELECTIVE NSAIDS MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 246. SWEDEN COX-2 SELECTIVE NSAIDS MARKET SIZE, BY ROUTE, 2018-2030 (USD MILLION)
TABLE 247. SWEDEN COX-2 SELECTIVE NSAIDS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 248. SWEDEN COX-2 SELECTIVE NSAIDS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 249. SWEDEN COX-2 SELECTIVE NSAIDS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 250. SWEDEN COX-2 SELECTIVE NSAIDS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 251. SWEDEN COX-2 SELECTIVE NSAIDS MARKET SIZE, BY ONLINE PHARMACY, 2018-2030 (USD MILLION)
TABLE 252. SWEDEN COX-2 SELECTIVE NSAIDS MARKET SIZE, BY RETAIL PHARMACY, 2018-2030 (USD MILLION)
TABLE 253. SWEDEN COX-2 SELECTIVE NSAIDS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 254. SWEDEN COX-2 SELECTIVE NSAIDS MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 255. SWEDEN COX-2 SELECTIVE NSAIDS MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 256. NIGERIA COX-2 SELECTIVE NSAIDS MARKET SIZE, BY ROUTE, 2018-2030 (USD MILLION)
TABLE 257. NIGERIA COX-2 SELECTIVE NSAIDS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 258. NIGERIA COX-2 SELECTIVE NSAIDS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 259. NIGERIA COX-2 SELECTIVE NSAIDS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 260. NIGERIA COX-2 SELECTIVE NSAIDS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 261. NIGERIA COX-2 SELECTIVE NSAIDS MARKET SIZE, BY ONLINE PHARMACY, 2018-2030 (USD MILLION)
TABLE 262. NIGERIA COX-2 SELECTIVE NSAIDS MARKET SIZE, BY RETAIL PHARMACY, 2018-2030 (USD MILLION)
TABLE 263. NIGERIA COX-2 SELECTIVE NSAIDS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 264. NIGERIA COX-2 SELECTIVE NSAIDS MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 265. NIGERIA COX-2 SELECTIVE NSAIDS MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 266. EGYPT COX-2 SELECTIVE NSAIDS MARKET SIZE, BY ROUTE, 2018-2030 (USD MILLION)
TABLE 267. EGYPT COX-2 SELECTIVE NSAIDS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 268. EGYPT COX-2 SELECTIVE NSAIDS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 269. EGYPT COX-2 SELECTIVE NSAIDS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 270. EGYPT COX-2 SELECTIVE NSAIDS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 271. EGYPT COX-2 SELECTIVE NSAIDS MARKET SIZE, BY ONLINE PHARMACY, 2018-2030 (USD MILLION)
TABLE 272. EGYPT COX-2 SELECTIVE NSAIDS MARKET SIZE, BY RETAIL PHARMACY, 2018-2030 (USD MILLION)
TABLE 273. EGYPT COX-2 SELECTIVE NSAIDS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 274. EGYPT COX-2 SELECTIVE NSAIDS MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 275. EGYPT COX-2 SELECTIVE NSAIDS MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 276. TURKEY COX-2 SELECTIVE NSAIDS MARKET SIZE, BY ROUTE, 2018-2030 (USD MILLION)
TABLE 277. TURKEY COX-2 SELECTIVE NSAIDS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 278. TURKEY COX-2 SELECTIVE NSAIDS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 279. TURKEY COX-2 SELECTIVE NSAIDS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 280. TURKEY COX-2 SELECTIVE NSAIDS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 281. TURKEY COX-2 SELECTIVE NSAIDS MARKET SIZE, BY ONLINE PHARMACY, 2018-2030 (USD MILLION)
TABLE 282. TURKEY COX-2 SELECTIVE NSAIDS MARKET SIZE, BY RETAIL PHARMACY, 2018-2030 (USD MILLION)
TABLE 283. TURKEY COX-2 SELECTIVE NSAIDS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 284. TURKEY COX-2 SELECTIVE NSAIDS MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 285. TURKEY COX-2 SELECTIVE NSAIDS MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 286. ISRAEL COX-2 SELECTIVE NSAIDS MARKET SIZE, BY ROUTE, 2018-2030 (USD MILLION)
TABLE 287. ISRAEL COX-2 SELECTIVE NSAIDS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 288. ISRAEL COX-2 SELECTIVE NSAIDS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 289. ISRAEL COX-2 SELECTIVE NSAIDS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 290. ISRAEL COX-2 SELECTIVE NSAIDS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 291. ISRAEL COX-2 SELECTIVE NSAIDS MARKET SIZE, BY ONLINE PHARMACY, 2018-2030 (USD MILLION)
TABLE 292. ISRAEL COX-2 SELECTIVE NSAIDS MARKET SIZE, BY RETAIL PHARMACY, 2018-2030 (USD MILLION)
TABLE 293. ISRAEL COX-2 SELECTIVE NSAIDS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 294. ISRAEL COX-2 SELECTIVE NSAIDS MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 295. ISRAEL COX-2 SELECTIVE NSAIDS MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 296. NORWAY COX-2 SELECTIVE NSAIDS MARKET SIZE, BY ROUTE, 2018-2030 (USD MILLION)
TABLE 297. NORWAY COX-2 SELECTIVE NSAIDS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 298. NORWAY COX-2 SELECTIVE NSAIDS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 299. NORWAY COX-2 SELECTIVE NSAIDS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 300. NORWAY COX-2 SELECTIVE NSAIDS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 301. NORWAY COX-2 SELECTIVE NSAIDS MARKET SIZE, BY ONLINE PHARMACY, 2018-2030 (USD MILLION)
TABLE 302. NORWAY COX-2 SELECTIVE NSAIDS MARKET SIZE, BY RETAIL PHARMACY, 2018-2030 (USD MILLION)
TABLE 303. NORWAY COX-2 SELECTIVE NSAIDS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 304. NORWAY COX-2 SELECTIVE NSAIDS MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 305. NORWAY COX-2 SELECTIVE NSAIDS MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 306. POLAND COX-2 SELECTIVE NSAIDS MARKET SIZE, BY ROUTE, 2018-2030 (USD MILLION)
TABLE 307. POLAND COX-2 SELECTIVE NSAIDS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 308. POLAND COX-2 SELECTIVE NSAIDS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 309. POLAND COX-2 SELECTIVE NSAIDS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 310. POLAND COX-2 SELECTIVE NSAIDS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 311. POLAND COX-2 SELECTIVE NSAIDS MARKET SIZE, BY ONLINE PHARMACY, 2018-2030 (USD MILLION)
TABLE 312. POLAND COX-2 SELECTIVE NSAIDS MARKET SIZE, BY RETAIL PHARMACY, 2018-2030 (USD MILLION)
TABLE 313. POLAND COX-2 SELECTIVE NSAIDS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 314. POLAND COX-2 SELECTIVE NSAIDS MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 315. POLAND COX-2 SELECTIVE NSAIDS MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 316. SWITZERLAND COX-2 SELECTIVE NSAIDS MARKET SIZE, BY ROUTE, 2018-2030 (USD MILLION)
TABLE 317. SWITZERLAND COX-2 SELECTIVE NSAIDS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 318. SWITZERLAND COX-2 SELECTIVE NSAIDS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 319. SWITZERLAND COX-2 SELECTIVE NSAIDS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 320. SWITZERLAND COX-2 SELECTIVE NSAIDS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 321. SWITZERLAND COX-2 SELECTIVE NSAIDS MARKET SIZE, BY ONLINE PHARMACY, 2018-2030 (USD MILLION)
TABLE 322. SWITZERLAND COX-2 SELECTIVE NSAIDS MARKET SIZE, BY RETAIL PHARMACY, 2018-2030 (USD MILLION)
TABLE 323. SWITZERLAND COX-2 SELECTIVE NSAIDS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 324. SWITZERLAND COX-2 SELECTIVE NSAIDS MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 325. SWITZERLAND COX-2 SELECTIVE NSAIDS MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 326. ASIA-PACIFIC COX-2 SELECTIVE NSAIDS MARKET SIZE, BY ROUTE, 2018-2030 (USD MILLION)
TABLE 327. ASIA-PACIFIC COX-2 SELECTIVE NSAIDS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 328. ASIA-PACIFIC COX-2 SELECTIVE NSAIDS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 329. ASIA-PACIFIC COX-2 SELECTIVE NSAIDS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 330. ASIA-PACIFIC COX-2 SELECTIVE NSAIDS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 331. ASIA-PACIFIC COX-2 SELECTIVE NSAIDS MARKET SIZE, BY ONLINE PHARMACY, 2018-2030 (USD MILLION)
TABLE 332. ASIA-PACIFIC COX-2 SELECTIVE NSAIDS MARKET SIZE, BY RETAIL PHARMACY, 2018-2030 (USD MILLION)
TABLE 333. ASIA-PACIFIC COX-2 SELECTIVE NSAIDS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 334. ASIA-PACIFIC COX-2 SELECTIVE NSAIDS MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 335. ASIA-PACIFIC COX-2 SELECTIVE NSAIDS MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 336. ASIA-PACIFIC COX-2 SELECTIVE NSAIDS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 337. CHINA COX-2 SELECTIVE NSAIDS MARKET SIZE, BY ROUTE, 2018-2030 (USD MILLION)
TABLE 338. CHINA COX-2 SELECTIVE NSAIDS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 339. CHINA COX-2 SELECTIVE NSAIDS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 340.

Companies Mentioned

The companies profiled in this COX-2 Selective NSAIDs market report include:
  • Pfizer Inc.
  • Merck & Co., Inc.
  • Novartis AG
  • Teva Pharmaceutical Industries Ltd.
  • Sandoz International GmbH
  • Dr. Reddy's Laboratories Ltd.
  • Lupin Limited

Methodology

Loading
LOADING...

Table Information

Report AttributeDetails
No. of Pages197
PublishedMay 2025
Forecast Period2025 - 2030
Estimated Market Value ( USD ) in 2025 $ 8.66 Billion
Forecasted Market Value ( USD ) by 2030 $ 11.34 Billion
Compound Annual Growth Rate5.5%
Regions CoveredGlobal
No. of Companies Mentioned8

Related Topics

Related Reports

Non-steroidal Anti-Inflammatory Drugs (NSAIDs) Market Report and Forecast 2024-2032 - Product Image

Non-steroidal Anti-Inflammatory Drugs (NSAIDs) Market Report and Forecast 2024-2032

  • Report
  • 200 Pages
  • Global
From
Non-steroidal Anti-inflammatory Drug Global Market Insights 2025, Analysis and Forecast to 2030, by Market Participants, Regions, Technology, Application, Product Type - Product Image

Non-steroidal Anti-inflammatory Drug Global Market Insights 2025, Analysis and Forecast to 2030, by Market Participants, Regions, Technology, Application, Product Type

  • Report
  • 101 Pages
  • Global
From
Non-Steroidal Anti-Inflammatory Drugs - Market Insights, Competitive Landscape, and Market Forecast - 2030 - Product Image

Non-Steroidal Anti-Inflammatory Drugs - Market Insights, Competitive Landscape, and Market Forecast - 2030

  • Drug Pipelines
  • 150 Pages
  • Global
From
Post Operative Pain Management - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts (2025 - 2030) - Product Image

Post Operative Pain Management - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts (2025 - 2030)

  • Report
  • 111 Pages
  • Global
From
Cyclo-oxygenase 2 Inhibitors - Pipeline Insight, 2025 - Product Image

Cyclo-oxygenase 2 Inhibitors - Pipeline Insight, 2025

  • Drug Pipelines
  • 90 Pages
  • Global
From
Copyright © 2002-2025 Research and Markets. All Rights Reserved.